$TRUMP
$XAU
Electra Therapeutics files for an initial public offering to fund immune disease drugs
Electra Therapeutics Inc. filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Friday, aiming to develop its pipeline of clinical-stage drugs targeting immune diseases and cancer. The San Francisco-based biotech company filed to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "ETRA".
The company’s lead drug candidate is eprobupat (Eisopropart), a monoclonal antibody designed for patients with secondary hemophagocytic lymphohistiocytosis syndrome. According to the submitted documents, there are no widely approved treatments for this acute inflammatory syndrome, and it is characterized by low survival rates. Eprobupat has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration, as well as "PRIORITY MEDICINE" designation from the European Medicines Agency for the treatment of secondary hemophagocytic lymphohistiocytosis syndrome.
#WarshSaysInflationIsFedTopFocus #SOLJumps20%OnTheWeek #CaliforniaBillWouldBarOfficialMemeCoins #$6.4BBitcoinOptionsExpire #TRONMainnetActivatesTVMPragueOsaka
$XAU
Electra Therapeutics files for an initial public offering to fund immune disease drugs
Electra Therapeutics Inc. filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Friday, aiming to develop its pipeline of clinical-stage drugs targeting immune diseases and cancer. The San Francisco-based biotech company filed to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "ETRA".
The company’s lead drug candidate is eprobupat (Eisopropart), a monoclonal antibody designed for patients with secondary hemophagocytic lymphohistiocytosis syndrome. According to the submitted documents, there are no widely approved treatments for this acute inflammatory syndrome, and it is characterized by low survival rates. Eprobupat has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration, as well as "PRIORITY MEDICINE" designation from the European Medicines Agency for the treatment of secondary hemophagocytic lymphohistiocytosis syndrome.
#WarshSaysInflationIsFedTopFocus #SOLJumps20%OnTheWeek #CaliforniaBillWouldBarOfficialMemeCoins #$6.4BBitcoinOptionsExpire #TRONMainnetActivatesTVMPragueOsaka
